Congressmen Question FDA on Loosening of Abortion-Inducing Drug Standards

(CNSNews.com) – Rep. Chris Smith (R-N.J.) and Sen. James Lankford (R-Okla.) sent a letter Monday, together with 73 of their colleagues to Food and Drug Administration (FDA) Commissioner Robert Califf, expressing concern and seeking information regarding the recent loosening of regulation of the abortion-inducing drug Mifeprex or RU-486.

The FDA announced a change in their guidelines for Mifeprex in March. The new guidelines reduce the dosage from 600 milligrams to 200 milligrams, decrease the number of required doctor’s visits from three to two, and allow the pill to be taken later in pregnancy, at 10 weeks of pregnancy from 7 weeks.

“We are deeply disappointed to learn that you have loosened FDA standards governing use of the abortion drug mifepristone, also referred to as Mifeprex or RU-486,” the lawmakers wrote. “This powerful abortion drug has been associated with serious adverse events including hemorrhaging, severe infections and even deaths of mothers who have taken it.”

“The Obama Administration’s gift to the abortion industry disregards the safety and lives of women.."

More here